Genetic control couples TGFβ-independent pluripotent stem cell renewal to deterministic forward programming across germ layers
Reproducible and scalable manufacture of human induced pluripotent stem cell (hiPSC) derivatives requires control over expansion and differentiation. Transcription factor-mediated forward programming can place hiPSC differentiation under genetic control, but expansion still relies on extracellular growth-factor supplementation, increasing process complexity and operator dependence. Here we introduce GERALT (Genetically Enhanced Renewal and Autonomous Lineage Transdifferentiation), a push-pull genetic circuit assembled through targeted safe-harbour integration that couples NANOG-supported, TGFβ-independent renewal to doxycycline-inducible lineage programming and simultaneous NANOG silencing. GERALT maintained pluripotency during extended TGFβ withdrawal in both adherent and suspension culture, yet remained programmable towards myogenic, neuronal, and hepatic fates. Compared with the established OPTi-OX platform in myogenesis, GERALT enabled differentiation in simplified medium while canalising and accelerating commitment. GERALT also supported direct myogenic programming in suspension and enabled direct casting of hiPSCs into hydrogel followed by in-tissue programming, yielding electrically responsive engineered muscle tissues. These results extend genetic control upstream into stem cell renewal, facilitating deployment of new approach methodologies and other biomanufacturing applications.
Authors
- David L. Mack (ORCID: https://orcid.org/0000-0003-1340-7056)
- Elisa Balmas (ORCID: https://orcid.org/0000-0002-4600-6809)
- Paolo Ettore Porporato (ORCID: https://orcid.org/0000-0001-8519-1552)
- Paola Defilippi (ORCID: https://orcid.org/0000-0001-6427-4906)
- Fabian Bachinger (ORCID: https://orcid.org/0009-0003-9889-3811)
- Ludovic Vallier (ORCID: https://orcid.org/0000-0002-3848-2602)
- Alec S.T. Smith (ORCID: https://orcid.org/0000-0002-0001-8484)
- Francesca Amodeo (ORCID: https://orcid.org/0009-0008-7578-1354)
- Alessandro Bertero (ORCID: https://orcid.org/0000-0002-4919-9087)
- Maddalena Arigoni (ORCID: https://orcid.org/0000-0003-4629-3841)
- Philip Barrett (ORCID: https://orcid.org/0000-0003-3963-4601)
- Sveva Bottini (ORCID: https://orcid.org/0009-0005-9137-1855)
- Divyashree Avnoor
- Mario De Gregorio (ORCID: https://orcid.org/0009-0005-1099-1420)
Institutions
- University of Washington (US)
- Berlin Institute of Health at Charité - Universitätsmedizin Berlin (DE)
- University of Turin (IT)
- Charité - Universitätsmedizin Berlin (DE)
Publication Details
- Journal
- bioRxiv (Cold Spring Harbor Laboratory)
- Published
- 2026-10-27
- DOI
- https://doi.org/10.64898/2026.10.25.761636
- Primary Topic
- Pluripotent Stem Cells Research
- Type
- preprint
Funders
- Giovanni Armenise-Harvard Foundation
- Compagnia di San Paolo
- University of Washington
- European Commission
- HORIZON EUROPE Framework Programme
- HORIZON EUROPE European Innovation Council
- NextGenerationEU